These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21209031)

  • 21. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome.
    Sam AH; Busbridge M; Amin A; Webber L; White D; Franks S; Martin NM; Sleeth M; Ismail NA; Daud NM; Papamargaritis D; Le Roux CW; Chapman RS; Frost G; Bloom SR; Murphy KG
    Diabet Med; 2013 Dec; 30(12):1495-9. PubMed ID: 23796160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.
    Arnold J; Sangwaiya A; Bhatkal B; Geoghegan F; Busbridge M
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):425-9. PubMed ID: 19262400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism.
    Luque-Ramírez M; Alpañés M; Escobar-Morreale HF
    Fertil Steril; 2010 Nov; 94(6):2214-21. PubMed ID: 20097337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepcidin resistance in dysmetabolic iron overload.
    Rametta R; Dongiovanni P; Pelusi S; Francione P; Iuculano F; Borroni V; Fatta E; Castagna A; Girelli D; Fargion S; Valenti L
    Liver Int; 2016 Oct; 36(10):1540-8. PubMed ID: 26998752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS).
    Ozgurtas T; Oktenli C; Dede M; Tapan S; Kenar L; Sanisoglu SY; Yesilova Z; Yenen MC; Erbil MK; Baser I
    Atherosclerosis; 2008 Oct; 200(2):336-44. PubMed ID: 18281049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
    Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced serum hepcidin levels in patients with chronic hepatitis C.
    Girelli D; Pasino M; Goodnough JB; Nemeth E; Guido M; Castagna A; Busti F; Campostrini N; Martinelli N; Vantini I; Corrocher R; Ganz T; Fattovich G
    J Hepatol; 2009 Nov; 51(5):845-52. PubMed ID: 19729219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.
    Eisenhardt S; Schwarzmann N; Henschel V; Germeyer A; von Wolff M; Hamann A; Strowitzki T
    J Clin Endocrinol Metab; 2006 Mar; 91(3):946-52. PubMed ID: 16352680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
    Palomba S; Falbo A; Russo T; Manguso F; Tolino A; Zullo F; De Feo P; Orio F
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3128-35. PubMed ID: 17519312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study.
    Palomba S; Falbo A; Chiossi G; Orio F; Tolino A; Colao A; La Sala GB; Zullo F
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2942-51. PubMed ID: 24873996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALTERED LEVELS OF ANTI-MULLERIAN HORMONE AND HEPCIDIN AS POTENTIAL BIOMARKERS FOR POLYCYSTIC OVARY SYNDROME.
    Jihad A; Sarhat E
    Georgian Med News; 2023 Jun; (339):47-51. PubMed ID: 37522773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of hepcidin level with insulin resistance and endocrine glands function in major thalassemia.
    Al-Hakeim HK; Al-Khakani MM; Al-Kindi MA
    Adv Clin Exp Med; 2015; 24(1):69-78. PubMed ID: 25923089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.
    O'Connor A; Phelan N; Tun TK; Boran G; Gibney J; Roche HM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1378-85. PubMed ID: 20080859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
    Hurliman A; Keller Brown J; Maille N; Mandala M; Casson P; Osol G
    Endocrinology; 2015 Nov; 156(11):4071-80. PubMed ID: 26322372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.